Rabusertib
Sign in to save this workspacePrimary targets: CHK1 · FDA status: FDA trials Discontinued after Phase II
Selectivity scorecard
KISS
98.74
Gini
0.687
CATDS
0.025
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Rabusertib. Strongest target: CHK1 at 99.4% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | CHK1 | 99.4% | 0.6% |
| 2 | RAF1 | 95.6% | 4.4% |
| 3 | CAMK2A | 92.0% | 8.0% |
| 4 | RSK3 | 91.1% | 8.9% |
| 5 | CAMK2D | 90.9% | 9.1% |
| 6 | RSK4 | 84.3% | 15.8% |
| 7 | CDK3_CYCLIN_C | 80.3% | 19.7% |
| 8 | RSK2 | 76.2% | 23.8% |
| 9 | TRKC | 75.2% | 24.8% |
| 10 | RSK1 | 74.3% | 25.7% |
| 11 | SIK2 | 72.1% | 27.9% |
| 12 | FLT3 | 71.2% | 28.8% |
| 13 | TNIK | 57.8% | 42.2% |
| 14 | BRSK2 | 56.9% | 43.1% |
| 15 | MEK5 | 53.9% | 46.1% |
| 16 | AMPK(A2_B2_G2) | 48.0% | 52.0% |
| 17 | LOK_STK10 | 47.4% | 52.6% |
| 18 | MSSK1_STK23 | 44.1% | 55.9% |
| 19 | AMPK(A2_B2_G1) | 41.9% | 58.1% |
| 20 | BRAF | 41.1% | 58.9% |
Selectivity landscape
Where Rabusertib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Rabusertib.
Annotations
Sign in to read and post annotations.
Loading…